Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 14/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13012231 | 0.85 | SSTR4 (0.42) | SSTR4ATRKDM4EALDH1A1TSHR | |
| SCHEMBL15408885 | 0.83 | SSTR4 (0.38) | SSTR4TSHRCHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL15322195 | 0.83 | SSTR4 (0.41) | SSTR4ATRSSTR1SSTR2SSTR3 | |
| Hydrochloric Acid SCHEMBL15322193 | 0.83 | SSTR4 (0.41) | SSTR4ATRSSTR1SSTR2SSTR3 | |
| SCHEMBL31464974 | 0.81 | CHRNB2 (0.53) | SSTR4KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL3556206 | 0.81 | SSTR4 (0.37) | SSTR4ATRSSTR1SSTR2SSTR3 | |
| SCHEMBL30860003 | 0.81 | CHRNB2 (0.53) | SSTR4KDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL13910560 | 0.76 | CYP2C9 (0.50) | KDM4EALDH1A1TSHRPOLB | |
| SCHEMBL13910692 | 0.74 | DPP9 (0.46) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL10403379 | 0.74 | SSTR4 (0.40) | SSTR4ATRSSTR1SSTR2SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| CN-101500569-A | HIF hydroxylase inhibitors for treatment of anemia of cancer | FIBROGEN INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101490041-A | 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | SSTR4 2255/4885ATR 1559/4885SSTR1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.